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Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of invasive
non-Hodgkin’s lymphoma (NHL). DLBCL presents with variable backgrounds, which results
in heterogeneous outcomes among patients. Although new tools have been developed for the
classification and management of patients, 40% of them still have primary refractory disease or
relapse. In addition, multiple factors regarding the pathogenesis of this disease remain unclear and
identification of novel biomarkers is needed. In this context, recent investigations point to microRNAs
as useful biomarkers in cancer. The aim of this systematic review was to provide new insight into
the role of miRNAs in the diagnosis, classification, treatment response and prognosis of DLBCL
patients. We used the following terms in PubMed” ((‘Non-coding RNA’) OR (‘microRNA’ OR ‘miRNA’
OR ‘miR’) OR (‘exosome’) OR (‘extracellular vesicle’) OR (‘secretome’)) AND (‘Diffuse large B cell
lymphoma’ OR ‘DLBCL’)” to search for studies evaluating miRNAs as a diagnosis, subtype, treatment
response or prognosis biomarkers in primary DLBCL in human patient populations. As a result,
the analysis was restricted to the role of miRNAs in tumor tissue and we did not consider circulating
miRNAs. A total of thirty-six studies met the inclusion criteria. Among them, twenty-one were
classified in the diagnosis category, twenty in classification, five in treatment response and nineteen
in prognosis. In this review, we have identified miR-155-5p and miR-21-5p as miRNAs of potential
utility for diagnosis, while miR-155-5p and miR-221-3p could be useful for classification. Further
studies are needed to exploit the potential of this field.
Keywords: lymphoma; microRNA; diagnosis; classification; treatment response; prognosis
1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults,
accounting for 30–40% of all non-Hodgkin lymphoma cases [1]. DLBCL presents a very diverse clinical
and genetic background, which leads to highly heterogeneous outcomes among patients [2].
The first line therapy for this aggressive malignancy consists of combined chemotherapy including
rituximab, prednisone, doxorubicin, vincristine and cyclophosphamide (R-CHOP). Around 75–80% of
patients achieve complete remission with R-CHOP therapy. Nevertheless, approximately up to 40 % of
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patients have primary refractory disease or relapse [3]. Worryingly, those patients tend to respond
poorly to additional chemotherapy lines, which remains a major cause of morbidity and mortality [4].
In order to identify DLBCL patients with a higher risk of a poor response to therapy, different
tools have been developed. The International Prognostic Index (IPI) predicts overall and progression
free survival based on five risk factors: age, tumor stage, serum lactate dehydrogenase (LDH)
concentration, performance status and number of extra nodal disease sites [5]. Using those factors, the
IPI distinguishes four risk groups with different 5-year overall survival, ranging from 26 to 73% [6].
Nevertheless, some patients present an unfavorable course of disease despite having a good prognostic
index. Another profiling tool uses gene expression profiling (GEP) or immunohistochemical analysis
to define two molecular subtypes with different clinical outcomes independent of IPI stratification:
the germinal center B-cell-like (GCB) DLBCL, and the activated B-cell-like (ABC) DLBCL. The 5-year
survival rates are 60% for GCB and 40% for ABC subtype [7,8]. However, it is not possible to identify
all the patients that will not respond to therapy with these profiling tools. Therefore, new biomarkers
are needed for a better patient stratification.
In this sense, important knowledge is emerging regarding novel molecular and biological
candidates with diagnostic, predictive and prognostic potential in DLBCL, including microRNAs
(miRNAs) [9]. MiRNAs are small, non-coding RNAs with a role in gene expression regulation at the
post-transcriptional level. They bind the 3′ untranslated region (UTR) of a target mRNA, which leads
to their repression or degradation [10]. Through this mechanism, miRNAs regulate more than 50% of
known human genes [11], including genes of the 10 main routes involved in cancer [12].
Accordingly, recent research has shown the potential role of miRNAs as diagnostic, classification
and prognostic predictors in cancer [13]. For instance, miR-21 has been intensively studied as a
diagnosis tool, being found upregulated in many types of cancer including non-small cell lung cancer
(NSCLC) [14]. Other examples include miR-10b, which has been described as a useful tool for the
classification of papillary renal cell carcinoma type 2 [15], and miR-183, high expression levels of which
have been associated with poor prognosis in different cancer types such as colorectal cancer, pancreatic
cancer, lung cancer, gastric cancer, and breast cancer [16].
Abnormal expression of miRNAs is also common in B cell neoplasms, including B cell lymphoma.
However, there is inconsistency in the data reported. Consequently, the aim of this systematic review
was to clarify the role of deregulated miRNAs in DLBCL tumor samples as more systematically-defined
diagnostic, subtype, prediction of treatment response and prognostic biomarkers.
2. Results
The detailed search results are included in Figure 1. In brief, the search strategy provided a total
of 508 records in the PubMed database. Once the duplicated articles were removed, 338 remained.
Of these 338, 239 were excluded after reading the abstract because they did not meet the inclusion
criteria. Then, the full texts of the remaining 99 studies, which focused on miRNAs in DLBCL, were
read carefully. Additionally, another 63 articles were excluded because there were other coexisting
pathologies, miRNAs were not analyzed in the tumor sample, DLBCL was not primarily considered,
they did not assess the role of miRNAs in diagnosis, subtype, prediction of treatment response or
prognosis, or miRNA expression changes were not considered. A total of 36 studies investigating the
role of miRNA expression changes as biomarkers in DLBCL tumor samples were included. Twenty-one
of them considered miRNAs as putative DLBCL diagnosis biomarkers, twenty in subtype classification,
five in treatment response and nineteen of the studies searched for markers for their role in prognosis.
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identified two miRNAs that were repeatedly reported to be up-regulated in DLBCL patients (miR-
155-5p [17,22,24,26,28,30,32–34], miR-21-5p [19,22,26,28,33,36], although some studies did not find a 
significant association (miR-155-5p [27,29], miR-21-5p [27,32]).We also identified two miRNAs with 
contradictory results. On the one hand, miR-150-5p was found to be down-regulated in DLBCL 
patients in four studies [18,28,31,32] and contradictorily up-regulated in DLBCL patients in another 
study [29], while no significant association was reported in the remaining study [27]. On the other 
hand, miR-146a/b-5p was found upregulated in three studies [22,27,30] while it was shown to be 
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two studies [27,28] (Table 1). 
2.2. Tumor Tissue miRNAs as Biomarkers for DLBCL Subtype Classification 
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DLBCL subtypes and their characteristics are provided in Table S2 [19,21,23–28,30,32–34,38–45]. 
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GCB samples, whereas miR-28-5p was found to be up-regulated [28,41] or unchanged [28,41] in the 
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Figure 1. Flow-chart diagram of study selection. k = number of records.
2.1. Tumor Tissue miRNAs as Biomarkers for Diagnosis in DLBCL
Twenty-one studies analyzed the expression of miRNAs by comparing DLBCL cases vs healthy
controls [17–37]. These 21 tudies provided a total f 140 differentially expressed microRNAs in DLBCL
patients compared with healthy control indivi uals as shown in Tabl S1.
Regarding he iRNAs that were conco da tly deregulated in more than two studies, we
identified two miRNAs that were repeatedly eported to be up-regulated in DLBCL pati nts
(miR-155-5p [17,22,24,26,28,30,32–34], miR-21-5p [19,22,26,28,33,36], although some studies did not
find a significant association (miR-155-5p [27,29], miR-21-5p [27,32]).We also id ntified two miRNAs
with contradictory results. On the one hand, miR-150 was found to be down-r gulated in DLBCL
patients in f ur studie [18,28,31,32] and contradictorily up-reg lated in DLBCL patien s in another
study [29], while no significant association was reported in the remaining study [27]. On the other
hand, miR-146a/b-5p was found upregulated in three studies [22,27,30] while it was shown to be
discor antly downregulated in another study [21], and not significantly associated ith DLBCL in
two tudies [27,28] (Table 1).
2.2. Tumor Tissue miRNAs as Biomarkers for DLBCL Subtype Classification
Twenty studies analyzed the role of tumor tissue miRNAs to distinguish between GCB and ABC
DLBCL subtypes and their characteristics are pr vided in Table S2 [19,21,23–28,30,32–34,38–45]. These
studies found 93 miRNAs differenti lly expressed between GCB nd ABC DLBCL samples. Among
these 93 differentially expressed miRNAs, five miRNA wer concordantly reported in more than
two studies. Four o th m wer report as down-regulated (miR-155-5p [26–28,30,33,34,38,41,44],
miR-221-3p [27,33,41,45], miR-222-3p [27,41,45], and miR-146a/b-5p [28,30,41]) or unchanged
(miR-221-3p [28,43], miR-22 -3p [28,32,38,43] and miR-146a/b-5p [21,27,28,38,43]) in GCB samples,
whereas miR-28-5p was found to be up-regulated [ ,41] or unchanged [28,41] in the same subtype
(Table 2).
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2.3. Tumor Tissue miRNAs as Biomarkers for Prediction of Treatment Response in DLBCL
Five studies were focused in the role of miRNAs in DLBCL tissue as predictive biomarkers
of response to R-CHOP treatment [18,23,24,30,42]. The characteristics of each study are shown in
Table S3. A total of five miRNAs were differentially expressed between good and poor responders.
Three microRNAs were found to be associated with a favorable response to therapy (miR-27-3p [18],
miR-34a-5p [24] and miR-224-5p [23]), whereas miR-155-5p [30] and miR-146-5p [30] were found to be
associated with chemoresistance. However, each miRNA was analyzed in only one study, without any
of the results being replicated.
2.4. Tumor Tissue miRNAs as Biomarkers for DLBCL Prognosis
The relevance of tumor tissue miRNAs for prognosis in DLBCL patients was analyzed in nineteen
studies [18,20,21,23,25–27,30,32,33,37,38,41,42,45–49]. A total of 50 miRNAs with significant reported
associations with patient survival were found (Table S4).
Considering the miRNAs with concordant significant results in more than two studies, miR-222-3p,
and miR-155-5p were identified. Up-regulation of miR-222-3p [45,48,49] and miR-155-5p [30,38,46]
was associated with a worse outcome in three different studies in each case. However, four and eight
studies, respectively, did not find any association with prognosis for miR-222-3p [27,32,41,47] and
miR-155-5p [26,27,32,33,41,47–49] (Table 3).
2.5. Pathway Enrichment Analysis
Predicted target genes for the miRNA that presented the highest evidence of being involved in
DLBCL diagnosis (miR-155-5p and miR-21-5p) and in subtype classification (miR-155-5p, miR-221-3p)
were identified in silico. Using these lists of genes, we searched for over-represented pathways that
could be linked to DLBCL.
MAPK signaling pathway—Homo sapiens (KEGG) was significantly enriched among the
predicted target genes of the two miRNAs associated with DLBCL diagnosis (Table S5). Regarding the
targets of the two miRNAs associated with DLBCL subtype, signaling by receptors tyrosine kinases
(Reactome) was significantly enriched (Table S6). The predicted target genes covered more than 20% of
the genes included in these two pathways (Table 4).
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Table 1. miRNAs significantly associated with DLBCL diagnosis in more than two studies.
Significant miRNAs Result n DLBCL n Control Sample Source Method n miRNAs Reference
29 32 (RLH) Tissue qRT-PCR 1 Li et al. 2017 [17]
22 6 (NLN) Biopsie qRT-PCR 1 Huskova et al. 2015 [24]
200 11 (NT) FFPE qRT-PCR 3 Go et al. 2015 [26]
45 (DC);75 (VC) 10 (DC);6 (VC) (NLN) FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
90 31 (RLN) FFPE qRT-PCR 2 Zhong et al. 2012 [30]
58 7 (NLN) FFPE qRT-PCR 157 Roehle et al. 2008 [32]
48 6 (NBC) FF and FFPE qRT-PCR 3 Lawrie et al. 2007 [33]
23 2 FF Semi RT-PCR 1 Eis et al. 2005 [34]
up
24 14 (NLN) FFPE array 3100 probes Tamaddon et al. 2016 [22]
92 15 FF sequencing miRNAome Lim 2015 et al. [27]
miR-155-5p
NS 12 7 FFPE qRT-PCR 4 Handal et al. 2013 [29]
miR-21-5p
up
55 20 (NLN) FF and FFPE qRT-PCR 1 Liu et al. 2017 [19]
26 10 (NLN) FFPE qRT-PCR 1 Song et al. 2017 [36]
200 11 (NT) FFPE qRT-PCR 3 Go et al. 2015 [26]
45 (DC);75 (VC) 10 (DC);6 (VC)(NLN) FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
48 6 (NBC) FF and FFPE qRT-PCR 3 Lawrie et al. 2007 [33]
24 14 (NLN) FFPE array 3100 probes Tamaddon et al. 2016 [22]
NS
92 15 FF sequencing miRNAome Lim et al. 2015 [27]
58 7 (NLN) FFPE qRT-PCR 157 Roehle et al. 2008 [32]
miR-150-5p
up 12 7 FFPE qRT-PCR 4 Handal et al. 2013 [29]
45 (DC);75 (VC) 10 (DC);6 (VC)(NLN) FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
36 5 (NLN) Tissue qRT-PCR 8 Fassina et al. 2012 [31]
58 7 (NLN) FFPE qRT-PCR 157 Roehle et al. 2008 [32]down
5 4 (RLH) Tissue nanostring 800 Jia et al. 2017 [18]
NS 92 15 FF sequencing miRNAome Lim et al. 2015 [27]
miR-146b-5p
down 106 30 (RLH) FFPE qRT-PCR 939 Wu et al. 2014 [21]
NS 45 (DC);75 (VC) 10 (DC);6 (VC)(NLN) FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
up
92 15 FF sequencing miRNAome Lim et al. 2015 [27]
24 14 (NLN) FFPE array 3100 probes Tamaddon et al. 2016 [22]
miR-146a-5p
90 31 (RLN) FFPE qRT-PCR 2 Zhong et al. 2012 [30]
24 14 (NLN) FFPE array 3100 probes Tamaddon et al. 2016 [22]
NS
45 (DC);75 (VC) 10 (DC);6 (VC)(NLN) FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
92 15 FF sequencing miRNAome Lim et al. 2015 [27]
RLH: Reactive lymphoid hyperplasia; NLN: normal lymph node tissues; NT: normal tonsil; FF: fresh frozen; FFPE: formalin-fixed paraffin-embedded; DC: discovery cohort; VC: validation
cohort; NBC: normal B cell samples; Up: statistically significantly upregulated in DLBCL patients; NS: no significant difference between patients and controls; Down: significantly
downregulated in DLBCL patients.
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Table 2. miRNAs significantly associated with DLBCL subtype in more than two studies.
Significant miRNAs Result n GCB n ABC Sample Source Method n miRNAs Reference
53 95 FFPE qRT-PCR 8 Go et al. 2015 [26]
32 27 FFPE qRT-PCR/array 377 Iqbal et al. 2015 [38]
20 34 FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
36 31 FF qRT-PCR 1 Huang et al. 2012 [44]
21 69 FFPE qRT-PCR 2 Zhong et al. 2012 [30]
32 28 FFPE Array 464 Lawrie et al. 2009 [41]
16 18 FF and FFPE qRT-PCR 3 Lawrie et al. 2007 [33]
4 19 FF Semiq. RT-PCR 1 Eis et al. 2005 [34]
miR-155-5p Down GCB
41 30 FF sequencing miRNAome Lim et al. 2015 [27]
NA 25 25 FFPE qRT-PCR 157 Roehle et al. 2008 [32]
miR-221-3p
Down GCB
11 18 FFPE qRT-PCR/array 470 Montes-Moreno et al. 2011 [45]
32 28 FFPE Array 464 Lawrie et al. 2009 [41]
16 18 FF and FFPE qRT-PCR 3 Lawrie et al. 2007 [33]
41 30 FF sequencing miRNAome Lim et al. 2015 [27]
NS
20 20 Tissue Array 113 Zhang et al. 2009 [43]
20 34 FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
11 18 FFPE qRT-PCR/array 470 Montes-Moreno et al. 2011 [45]
32 28 FFPE Array 464 Lawrie et al. 2009 [41]Down GCB
41 30 FF sequencing miRNAome Lim et al. 2015 [27]
25 25 FFPE qRT-PCR 157 Roehle et al. 2008 [32]
20 20 Tissue Array 113 Zhang et al. 2009 [43]
32 27 FFPE qRT-PCR/array 377 Iqbal et al. 2015 [38]
miR-222-3p
NS
20 34 FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
miR-146a-5p
Down GCB 20 34 FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
21 69 FFPE qRT-PCR 2 Zhong et al. 2012 [30]
NS
41 30 FF sequencing miRNAome Lim et al. 2015 [27]
20 20 Tissue Array 113 Zhang et al. 2009 [43]
miR-146b-5p
Down GCB 32 28 FFPE Array 464 Lawrie et al. 2009 [41]
NS
32 27 FFPE qRT-PCR/array 377 Iqbal et al. 2015 [38]
41 30 FF sequencing miRNAome Lim et al. 2015 [27]
20 20 Tissue Array 113 Zhang et al. 2009 [43]
47 59 FFPE qRT-PCR 2 Wu et al. 2014 [21]
20 34 FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
11 18 FFPE qRT-PCR/array 470 Montes-Moreno et al. 2011 [45]
32 27 FFPE qRT-PCR/array 377 Iqbal et al. 2015 [38]
41 30 FF sequencing miRNAome Lim et al. 2015 [27]
Up GCB
20 20 Tissue Array 113 Zhang et al. 2009 [43]
20 34 FF and FFPE qRT-PCR/array 177 Caramuta et al. 2013 [28]
miR-28-5p
NS 32 28 FFPE Array 464 Lawrie et al. 2009 [41]
GCB: Germinal center B-cell like; FF: fresh frozen; FFPE: formalin-fixed paraffin-embedded; NA: not available; Up: statistically significantly upregulated in the subtype of DLBCL patients;
NS: no significant difference between patient subtypes; Down: significantly downregulated in the subtype of DLBCL patients.
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Table 3. miRNAs significantly associated with DLBCL prognosis in more than two studies.
Significant miRNAs Result n DLBCL Sample Source Method n miRNAs Reference
Up: ↓OS 176 FFPE qRT-PCR 11 Alencar et al. 2011 [48]
Up: ↓PFS and OS 36/240 FFPE qRT-PCR/array 470/9 Montes-Moreno et al. 2011 [45]
Up: ↓OS and PFS 106 FFPE qRT-PCR 3 Malumbres et al. 2009 [49]
64 FFPE Array 464 Lawrie et al. 2009 [41]
92 FF sequencing miRNAome Lim et al. 2015 [27]
58 Biopsie qRT-PCR 157 Roehle et al. 2008 [32]
miR-222-3p
NS
83 FFPE qRT-PCR/array ±900 Shepshelovich et al. 2015 [47]
miR-155-5p
Up: ↓survival 118 FF qRT-PCR 1 Zhu et al. 2016 [46]
Up: ↓OS 79 FFPE qRT-PCR 8 Iqbal et al. 2015 [38]
Down: ↑PFS 90 FFPE qRT-PCR 2 Zhong et al. 2012 [30]
NS
176 FFPE qRT-PCR 11 Alencar et al. 2017 [48]
200 FFPE qRT-PCR 3 Go et al. 2015 [26]
35 FF and FFPE qRT-PCR 3 Lawrie et al. 2007 [33]
64 FFPE Array 464 Lawrie et al. 2009 [41]
92 FF sequencing miRNAome Lim et al. 2015 [27]
106 FFPE qRT-PCR 3 Malumbres et al. 2009 [49]
58 Biopsie qRT-PCR 157 Roehle et al. 2008 [32]
83 FFPE qRT-PCR/array ±900 Shepshelovich et al. 2015 [47]
FF: fresh frozen; FFPE: formalin-fixed paraffin-embedded; OS: overall survival; PFS: progression-free survival; EFS: event free survival; RFS: relapse free survival; Up: statistically
significantly upregulated expression; NS: no significant association between expression and patient outcome; Down: significantly downregulated expression. ↓: decreased; ↑: increased.
Table 4. Coverage of DLBCL related pathway with miRNA predicted targets.
Phenotype
Pathway Name
miRNA p-value FDR n Target Genes CoverageNum. of Genes
Database
DLBCL Diagnosis




miR-21-5p 3.42 × 10
−07 0.000293 73 24.7%
DLBCL
Subtype





−07 6.25 × 10−05 103 24.4%
p-value: absolute p-value; FDR: corrected p-value by “False Discovery Rate” method; pathway source: associated database.
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3. Discussion
In this systematic review, we have performed an in depth analysis of the current literature in
relation to the potential role of miRNA expression in tumor biopsies as biomarker for diagnosis,
subtype characterization, treatment response and prognosis in patients with DLBCL.
Regarding the suitability of miRNAs as diagnostic biomarkers in DLBCL, twenty one
articles were identified, in which a total of four miRNAs (miR-155-5p [17,22,24,26,28,30,32–34],
miR-21-5p [19,22,26,28,33,36], miR-150-5p [18,28,29,31,32]) and miR-146a/b-5p [21,22,27,30] were
found to be significantly deregulated in DLBCL patients in more than two studies with concordant
results. Among them, miR-155-5p and miR-21-5p presented the most consistent results, being found
upregulated in DLBCL patients in most studies.
MiR-155-5p, was the most widely studied miRNA and was found to be upregulated in DLBCL
patients in nine of the studies in which it was analyzed [17,22,24,26,28,30,32–34] while no significant
association was found in the other two studies [27,29]. Among the two studies that did not find
a significant association between mir-155-5p and DLBCL, one presented the smallest sample size
with nineteen patients [29], and the other study followed stricter criteria for statistically significant
associations [27]. In agreement with these results, previous studies have suggested that miR-155 could
represent an onco-miR as its expression is activated in many tumors, i.e., prostate cancer, breast cancer,
and other tumors, particularly those of the lymphoid tissue [50–52]. A possible explanation for its
implication in DLBCL is that the validated targets of this miRNA include known hallmarks of DLBCL,
such as SOSC or SHIP1 [53].
On the other hand, it is noteworthy that miR-21-5p, which was analyzed in eight independent
studies, was significantly upregulated in DLBCL patients in six of them [19,22,26,28,33,36], while no
statistically significant association was found in the other two studies [27,32]. In agreement with this
observation, miR-21 has been reported to be deregulated in most cancers, such as colorectal cancer,
acting as an oncogene [54]. High levels of miR-21 have also been observed in B-NHLs. Overall,
miR-21 is considered to be an onco-miR that acts through the inhibition of the expression of different
phosphatases, such as PDCD4 (Programmed Cell Death 4) and PTEN (Phosphatase And Tensin
Homolog), which control the activity of signaling pathways like AKT and MAPK [55].
Given that miR-155-5p and miR-21-5p seem the best candidates as putative diagnostic tools in
patients with DLBCL, their functional implication was inferred by in silico analysis. This analysis
showed that MAPK signaling pathway is over-represented among the combined predicted target
genes of miR-155-5p and miR-21-5p (Table 4). Interestingly, the genes predicted to be targeted by
miR-155-5p and miR-21-5p are in the first steps of the signaling cascade (CACN, RTK, IL1R or NIK).
Aberrant expression of this pathway is a major and highly prevalent oncogenic event in many human
cancers [56], including NHL [57], which could explain the role of these miRNAs in DLBCL. In this
regard, miR-21-5p is also one of the most frequently upregulated circulating microRNAs previously
described as a non-invasive diagnosis biomarker [9].
The utility of microRNAs for DLBCL classification has been analyzed by twenty studies. A total
of five miRNAs (miR-155-5p [26–28,30,33,34,38,41,44], miR-221-3p [27,33,41,45], miR-222-3p [27,41,45],
miR-146a/b-5p [28,41,43], and miR-28-5p [27,38,43,45]) were found to be deregulated in more than
two studies. However, miR-222-3p, miR-146a/b-5p, and miR-28-5p showed contradictory results
since they were not found to be significantly related to DLBCL classification in four [28,32,38,43],
five [21,27,28,38,43] and two studies [28,41], respectively. Some of the discrepancies might be due to
the fact that subtype classification of the DLBCL patients was performed by GEP or IHC, which makes
the studies less comparable due to the variable reproducibility of IHC stains and interpretations. The
only miRNAs that showed more consistent results were miR-155-5p and miR-221-3p. MiR-155-5p
was found to be upregulated in the ABC subgroup in nine out of ten studies and only found to be
not associated in a study which used IHC for classification and a more stringent requirement for
differentially expressed miRNAs [32]. Mir-221-3p was found to be upregulated in the ABC subgroup
in four of the six studies in which it was analyzed.
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Taking into account the two most consistent microRNAs related with DLBCL classification,
miR-155-5p and miR-221-3p, in silico analysis showed that the Tyrosine Kinase pathway was
over-represented among their predicted target genes (Table 4). Among the target genes of both
microRNAs, we found PIK3R1 (p85), which is a negative regulator of the phosphatidylinositol 3-kinase
(PI3K)-AKT pathway. Our data could indicate that overexpression of miR-155-5p and miR-221-3p in
ABC subgroup repressed PIK3R1 (p85), the PIK regulatory subunit, activating the PI3K-AKT signaling
pathway in this subtype. However, it should be noted that it would be difficult to classify different
DLBCL subtypes simply based on those two miRNAs. Thus, additional molecular biomarkers would
be needed for clinical application.
Focusing on miRNAs as predictive biomarkers of response to R-CHOP treatment, five studies were
identified with no agreement in the miRNAs considered [18,23,24,30,42]. Among them, upregulation
of miR-27-3p [18], miR-34a-5p [42] and miR-224-5p [23] were associated with chemosensitivity and
miR-155-5p and miR-146-5p [30] were associated with chemoresistance (Table S3). Further studies are
needed to confirm these preliminary results.
Finally, the implications of microRNAs in prognosis in DLBCL has been analyzed in nineteen
studies including 50 significant miRNAs [18,20,21,23,25–27,30,32,33,41,42,45–49]. Among them, the
expression of miR-222-3p [45,48,49], and miR-155-5p [30,38,46] were found to be associated with
prognosis in more than two studies with concordant results. However, these miRNAs were analyzed
in an equal or higher number of additional studies without finding any association with prognosis,
which means that none of the analyzed miRNAs were established as a reliable marker of prognosis.
It is noteworthy that most studies failed to report the specific treatment regimens, which would
be of relevance in order to find prognostic biomarkers since prognosis is dependent on the specific
treatment regimen.
Several limitations were faced while performing this systematic review. On the one hand, the
studies performed usually considered a limited set of selected miRNAs, which limits the number
of comparable results and centers the discussion on those miRNAs that are better known, leaving
other miRNAs aside. It is necessary to perform large-scale studies with a wider array of miRNAs
using techniques such as next-generation sequencing that allow the identification of new miRNAs. On
the other hand, most studies analyzed in this revision relied on tissue-based miRNA detection using
qRT-PCR. As a result, it is difficult to know whether the differentially expressed miRNAs directly
result from DLBCL or from the cancer-associated microenvironment. Single-cell RNA sequencing
methods, developed in recent years, may provide a better approach to achieve this goal in future
studies. Further, the included studies present great heterogeneity in sample sources, types of controls
used or methodology for expression analysis. This methodological variability could be a source of
differences in results among studies. Since the effect of such differences is difficult to determine
in the context of a review, it would be of great relevance to reach a consensus and standardize the
methodology of study used for future studies in order to facilitate reproducibility and comparisons
among studies.
In addition, there is variability in the cut-off value for statistical significance among studies, which
we considered to be a potential source of heterogeneity. Finally, there is a tendency to only publish
statistically significant results, which leads to bias. All of these limitations in the published literature
may be contributing to the lack of consistency in many of the results, which makes it difficult to draw
final conclusions about the role of some of the miRNAs analyzed as biomarkers in DLBCL.
4. Materials and Methods
4.1. Systematic Review
4.1.1. Search Strategy
A systematic search with the terms “((‘Non-coding RNA’) OR (‘miRNA’ OR ‘microRNA’ OR ‘miR’)
OR (‘exosome’) OR (‘extracellular vesicle’) OR (‘secretome’)) AND (‘Diffuse large B cell lymphoma’
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OR ‘DLBCL’)”, following the same strategy used in our previously published review on circulating
miRNAs [9] was performed using the PubMed database (https://www.ncbi.nlm.nih.gov/pubmed/),
including articles published until December 2017.
4.1.2. Inclusion and exclusion criteria
Independent original studies that evaluated the expression of miRNAs in DLBCL tumor tissue
as diagnosis, subtype, prediction of treatment response or prognosis biomarkers in human patient
populations were included. Exclusion criteria encompassed: articles not including original data
(reviews, meta-analyses, letters, and comments), case reports, abstracts, articles not published in
English, studies that did not include miRNA data on human populations, and studies on diseases
other than DLBCL. After full text revision, articles that included other diseases, analyzed circulating
miRNAs, were focused on non-primary DLBCL, did not assess the role of miRNAs in diagnosis,
subtype, treatment response, or prognosis, or did not analyze miRNA expression, were excluded.
References within the identified studies were reviewed to identify additional matches. Study selection
was performed by two researchers independently (AL and BS) and disagreements were resolved
by consensus.
4.1.3. Data Extraction
The following information was extracted from each study: publication year, type of tissue sample
analyzed, characteristics of the study population, methodology, number of miRNAs studied, and the
list of differentially expressed miRNAs provided. Only the miRNAs that were reported as statistically
significant in more than two studies with consistent results were selected.
4.2. Data Analysis
4.2.1. Target Genes Selection
In order to predict the putative target genes for the miRNAs identified in the systematic search,
miRWalk 2.0 database (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/) [58] was used.
Only those genes predicted by 6 or more of the 12 available prediction algorithms available at miRWalk
2.0 were taken into account.
4.2.2. Pathway Enrichment Analysis
In order to analyze pathways enrichment within the lists of predicted target genes,
the over-representation analysis module of the ConsensusPathDB web tool (CPdB) (http://
consensuspathdb.org/) was used [59]. Within this tool, KEGG (https://www.genome.jp/kegg/) [60],
Reactome (https://reactome.org/PathwayBrowser/) [61] and BioCarta (http://cgap.nci.nih.gov/
Pathways/BioCarta_Pathways) databases were interrogated, assuming a conservative p-value cutoff
of 0.0001.
5. Conclusions
In this systematic review, we have identified that the expression of miR-155-5p and mir-21-5p
shows the potential for utility in diagnosis, while mir-155-5p and mir-21-5p could be of use for DLBCL
classification. Nevertheless, other associations between miRNA expression and DLBCL phenotypes
showed contradictory results. We can conclude that this is a very promising field of study, which could
also help to identify novel therapeutic targets and strategies to guide treatment choice. In order to
exploit the potential of this field, it would be of particular interest to perform large-scale studies with
large sample sizes and a wider array of miRNAs, including unknown miRNAs.
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